Author

H. Bi̇nokay

h-index 5 View on Semantic Scholar

We have 4 of 57 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Artificial intelligence in eating disorder research: a scoping review with bibliometric analysis of trends, methodologies, and translational readiness (2016–2025)

Artificial intelligence (AI) applications in eating disorder research have expanded rapidly, yet the structure, scope, and translational readiness of this literature have not been systematically mapped. This study aimed to characterise publication trends, AI methodologies, clinical application domains, data sources, an...

Yasin Çalışkan, Mesut Sarı, H. Bi̇nokay · Eating and Weight Disorders · 0 citations

Open access Aug 2026

The impact of sleep habits on emotional and behavioral problems, quality of life, caregiver depression, and burnout in children with autism spectrum disorder

Background Sleep disturbances affect 40–80% of children with autism spectrum disorder (ASD), yet their concurrent associations with neurobehavioral functioning, health-related quality of life (HRQoL), and primary caregiver mental health remain insufficiently characterized within an integrated multivariate framework tha...

Asiye Arıcı Gürbüz, Semiha Cömertoğlu Arslan, Seda Bozduman Çelebi et al. · Frontiers in Psychiatry · 0 citations

Open access Aug 2026

EEG Connectivity Signatures in Migraine and Tension-Type Headache: A Multimethod ROI-Based Functional Connectivity and Machine-Learning Analysis

The results point to method-dependent, region-specific sensor-level EEG differences across migraine, TTH, and control groups that are best viewed as candidate neurophysiological signatures rather than clinically ready biomarkers.

Z. Şanlı, Ismail Çalıkuşu, Pamir Bastin et al. · Journal of Clinical Medicine · 0 citations

Open access Aug 2026

EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study

These exploratory findings do not support the clinical use of EZH2 as a biomarker at this stage; prospective, multicenter studies using predefined thresholds and standardized immunohistochemical methods are needed to clarify its potential role as a marker complementary to PD-L1.

E. Asarkaya, Hatice Asoğlu, Abdurrahman Aykut et al. · Journal of Clinical Medicine · 0 citations